All questionsDrug interactions: Verzenio (abemaciclib), all indications5 questions · 1 sourceDrug interactionsWhat drug interactions does Verzenio have?“Strong and moderate CYP3A4 inhibitors increased the exposure of abemaciclib plus its active metabolites to a clinically meaningful extent and may lead to increased toxicity.” (opens the source at this quote in a new tab)CopyFlag“Avoid concomitant use of ketoconazole. Ketoconazole is predicted to increase the AUC of abemaciclib by up to 16-fold [see Clinical Pharmacology (12.3)].” (opens the source at this quote in a new tab)CopyFlag“Coadministration of strong or moderate CYP3A inducers decreased the plasma concentrations of abemaciclib plus its active metabolites and may lead to reduced activity. Avoid concomitant use of strong or moderate CYP3A inducers and consider alternative agents [see Clinical Pharmacology (12.3)].” (opens the source at this quote in a new tab)CopyFlag“Advise patients to inform their healthcare providers of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, and herbal products [see Dosage and Administration (2.2) and Drug Interactions (7)].” (opens the source at this quote in a new tab)CopyFlagWhat Verzenio dose is used with a strong CYP3A inhibitor?“Avoid concomitant use of the strong CYP3A inhibitor ketoconazole.” (opens the source at this quote in a new tab)CopyFlag“With concomitant use of strong CYP3A inhibitors other than ketoconazole, in patients with recommended starting dosage of 200 mg twice daily or 150 mg twice daily, reduce the VERZENIO dosage to 100 mg twice daily. In patients who have had a dosage reduction to 100 mg twice daily due to adverse reactions, further reduce the VERZENIO dosage to 50 mg twice daily. If a patient taking VERZENIO discontinues a CYP3A inhibitor, increase the VERZENIO dosage (after 3-5 half-lives of the inhibitor) to the dose that was used before starting the strong inhibitor [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].” (opens the source at this quote in a new tab)CopyFlag“With concomitant use of moderate CYP3A inhibitors, monitor for adverse reactions and consider reducing the VERZENIO dose in 50 mg decrements as demonstrated in Table 1, if necessary.” (opens the source at this quote in a new tab)CopyFlagCan Verzenio be taken with grapefruit?“Grapefruit may interact with VERZENIO. Advise patients not to consume grapefruit products while on treatment with VERZENIO.” (opens the source at this quote in a new tab)CopyFlag“Avoid grapefruit and products that contain grapefruit during treatment with VERZENIO. Grapefruit may increase the amount of VERZENIO in your blood.” (opens the source at this quote in a new tab)CopyFlagNote: The second passage is from the Patient Information printed with the Prescribing Information.Does Verzenio interact with loperamide?“Loperamide: Co-administration of a single 8 mg dose of loperamide with a single 400 mg dose of abemaciclib in healthy subjects increased the relative potency adjusted unbound AUC0-INF of abemaciclib plus its active metabolites (M2 and M20) by 12%, which is not considered clinically relevant.” (opens the source at this quote in a new tab)CopyFlag“Loperamide: In a clinical drug interaction study in healthy subjects, coadministration of a single 8 mg dose of loperamide with a single 400 mg abemaciclib (2.7 times the approved recommended 150 mg dosage) increased loperamide AUC0-INF by 9% and Cmax by 35% relative to loperamide alone. These increases in loperamide exposure are not considered clinically relevant.” (opens the source at this quote in a new tab)CopyFlagDoes Verzenio interact with metformin?“Metformin: In a clinical drug interaction study in healthy subjects, coadministration of a single 1000 mg dose of metformin, a clinically relevant substrate of renal OCT2, MATE1, and MATE2-K transporters, with a single 400 mg dose of abemaciclib (2.7 times the approved recommended 150 mg dosage) increased metformin AUC0-INF by 37% and Cmax by 22% relative to metformin alone. Abemaciclib reduced the renal clearance and renal secretion of metformin by 45% and 62%, respectively, relative to metformin alone, without any effect on glomerular filtration rate (GFR) as measured by iohexol clearance and serum cystatin C.” (opens the source at this quote in a new tab)CopyFlag